Optison (Perflutren)

Perflutren consists of microbubbles that are highly reflective to ultrasound energy. After intravenous administration, these microbubbles circulate in the bloodstream and amplify the acoustic signal returned from blood‑filled structures. The resulting increase in echogenicity provides sharper contrast between cardiac tissues and blood, allowing detailed visualization of cardiac anatomy during ultrasound examinations.

The dose of Optison is determined by the prescribing physician based on the specific imaging protocol and patient characteristics. Typically, a single vial is reconstituted and administered as an intravenous bolus immediately before the ultrasound study, but exact volume and timing are set by the healthcare provider.

Limited clinical data are available on the use of Optison during pregnancy or lactation. Because safety has not been established, it is generally avoided in pregnant or breastfeeding women unless the potential diagnostic benefit outweighs any possible risk, and the decision is made by the treating physician.

To order Optison, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Optison (perflutren) and Definity (another perflutren formulation) are both microbubble‑based ultrasound contrast agents with similar imaging performance. Compared with sulfur‑hexafluoride agents such as SonoVue, perflutren agents generally have a slightly longer intravascular lifespan and may produce stronger backscatter, but individual choice depends on regulatory approval, physician preference and specific imaging protocol requirements.

Optison must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing. Do not shake the suspension vigorously; gently invert to mix if needed before reconstitution. Maintaining the cold‑chain ensures stability of the microbubble formulation.

Optison is supplied as a sterile suspension for injection. The vial is reconstituted with the provided diluent, gently mixed, and then administered intravenously as a rapid bolus immediately before the ultrasound examination. The injection is performed by a qualified healthcare professional under monitoring of vital signs.

The most serious risks include severe allergic reactions such as anaphylaxis, marked hypotension that may require medical intervention, and cardiac arrhythmias. Patients should be closely observed during and after injection, and emergency equipment should be readily available to manage any acute adverse events.

Optison is contraindicated in individuals with known hypersensitivity to perflutren or any component of the formulation. It should also be avoided in patients with severe pulmonary hypertension, unstable cardiac conditions (e.g., acute myocardial infarction, decompensated heart failure) and those who have experienced severe reactions to other ultrasound contrast agents.